drugset / Trial / NCT01878474

Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TA-8995 With Single, Escalating Doses in Healthy Subjects

NCT01878474

Phase 1 Completed 96 enrolled Tanabe Pharma Corporation
RandomizedSingle-groupDouble-blindTreatment

Summary

The purpose of this study is to assess the safety and tolerability of single doses of TA-8995 in healthy Caucasian and Japanese volunteers.

Timeline

Start
2008-03
Primary completion
2009-06
Completion
2009-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Obicetrapib Small molecule 5 mg
Subject Obicetrapib Small molecule 10 mg
Subject Obicetrapib Small molecule 25 mg
Subject Obicetrapib Small molecule 50 mg
Subject Obicetrapib Small molecule 100 mg
Subject Obicetrapib Small molecule 150 mg

Indications